A potent class of GPR40 full agonists engages the enteroinsular axis to promote glucose control in rodents.

A potent class of GPR40 full agonists engages the enteroinsular axis to promote glucose control in rodents.
复制标题

一类强效 GPR40 完全激动剂可作用于肠岛轴,促进啮齿类动物的血糖控制。

DOI:
10.1371/journal.pone.0046300
复制
发表时间:
2012
期刊:
影响因子:
3.7
通讯作者:
Lin DC
Lin DC
中科院分区:
综合性期刊3区
文献类型:
--
作者:
Luo J;Swaminath G;Brown SP;Zhang J;Guo Q;Chen M;Nguyen K;Tran T;Miao L;Dransfield PJ;Vimolratana M;Houze JB;Wong S;Toteva M;Shan B;Li F;Zhuang R;Lin DC

文献摘要

参考文献

被引文献

相似文献

2型糖尿病的特征在于由于胰岛素分泌缺陷、胰岛素抵抗和肠促胰岛素应答而导致的葡萄糖稳态受损。GPR 40(FFAR 1或FFA 1)是一种G蛋白偶联受体(GPCR),主要在小肠的胰岛素产生胰腺β细胞和肠促胰岛素产生肠内分泌细胞中表达。已经公开了几种GPR 40激动剂,包括AMG 837和TAK-875,但是没有报道GPR 40合成激动剂同时参与胰岛素和肠促胰岛素轴。在这份报告中,我们提供了一个分子解释,并描述了一个独特的和有效的GPR 40完全激动剂,从事肠胰岛轴,以促进啮齿动物的血糖控制显着改善的发现。GPR 40完全激动剂AM-1638和AM-6226刺激GLP-1和GIP从肠内分泌细胞分泌,并增加来自胰岛的GSIS,导致2型糖尿病的高脂肪喂养、链脲佐菌素治疗和NONCNZO 10/LtJ小鼠模型中的葡萄糖控制增强。在GLP-1受体拮抗剂Ex(9-39)NH 2存在下,AM-1638对高血糖症的改善作用降低。
Type 2 diabetes is characterized by impaired glucose homeostasis due to defects in insulin secretion, insulin resistance and the incretin response. GPR40 (FFAR1 or FFA1) is a G-protein-coupled receptor (GPCR), primarily expressed in insulin-producing pancreatic β-cells and incretin-producing enteroendocrine cells of the small intestine. Several GPR40 agonists, including AMG 837 and TAK-875, have been disclosed, but no GPR40 synthetic agonists have been reported that engage both the insulinogenic and incretinogenic axes. In this report we provide a molecular explanation and describe the discovery of a unique and potent class of GPR40 full agonists that engages the enteroinsular axis to promote dramatic improvement in glucose control in rodents. GPR40 full agonists AM-1638 and AM-6226 stimulate GLP-1 and GIP secretion from intestinal enteroendocrine cells and increase GSIS from pancreatic islets, leading to enhanced glucose control in the high fat fed, streptozotocin treated and NONcNZO10/LtJ mouse models of type 2 diabetes. The improvement in hyperglycemia by AM-1638 was reduced in the presence of the GLP-1 receptor antagonist Ex(9–39)NH2.
DOI: 10.1016/s0026-0495(98)90027-0
发表时间: 1998-06-01
影响因子: 9.8
作者:
Luo, J;Quan, J;Reaven, GM
通讯作者: Reaven, GM
DOI: 10.4065/mcp.2010.0469
发表时间: 2010-12-01
影响因子: 8.9
作者:
Davidson, Jaime A
通讯作者: Davidson, Jaime A
DOI: 10.2337/db08-0307
发表时间: 2008-09
期刊: Diabetes
影响因子: 7.7
作者:
Edfalk S;Steneberg P;Edlund H
通讯作者: Edlund H
DOI: 10.1021/jm8010178
发表时间: 2008-11-27
影响因子: 7.3
作者:
Christiansen, Elisabeth;Urban, Christian;Ulven, Trond
通讯作者: Ulven, Trond
DOI: 10.1038/sj.bjp.0706770
发表时间: 2006-07-01
影响因子: 7.3
作者:
Briscoe, Celia P.;Peat, Andrew J.;Jenkinson, Stephen
通讯作者: Jenkinson, Stephen